These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 33041111)

  • 21. Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
    Miller-Handley H; Luckett K; Govil A
    Adv Chronic Kidney Dis; 2020 Sep; 27(5):434-441. PubMed ID: 33308510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.
    Raj CTD; Kandaswamy DK; Danduga RCSR; Rajasabapathy R; James RA
    Arch Microbiol; 2021 Jul; 203(5):2043-2057. PubMed ID: 33555378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remdesivir for the treatment of COVID-19.
    Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of SARS-CoV-2: How far have we reached?
    Ahsan W; Javed S; Bratty MA; Alhazmi HA; Najmi A
    Drug Discov Ther; 2020 May; 14(2):67-72. PubMed ID: 32336723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2.
    Alsharif MH; Alsharif YH; Albreem MA; Jahid A; Solyman AAA; Yahya K; Alomari OA; Hossain MS
    Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11977-11981. PubMed ID: 33275275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
    Yadav AK; Wen S; Xu X; Yu L
    Ann Palliat Med; 2021 Jan; 10(1):707-720. PubMed ID: 33440983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Some drugs for COVID-19.
    Med Lett Drugs Ther; 2020 Apr; 62(1595):49-50. PubMed ID: 32324177
    [No Abstract]   [Full Text] [Related]  

  • 28. Psychopharmacology of COVID-19.
    Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
    Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
    Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
    SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential therapeutic agents against COVID-19: What we know so far.
    Lu CC; Chen MY; Lee WS; Chang YL
    J Chin Med Assoc; 2020 Jun; 83(6):534-536. PubMed ID: 32243270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
    Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
    Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.
    Bhattacharyya A; Kumar S; Sarma P; Kaur H; Prajapat M; Shekhar N; Bansal S; Avti P; Hazarika M; Sharma S; Mahendru D; Prakash A; Medhi B
    Indian J Pharmacol; 2020; 52(4):313-323. PubMed ID: 33078733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
    Bokharee N; Khan YH; Khokhar A; Mallhi TH; Alotaibi NH; Rasheed M
    Expert Rev Anti Infect Ther; 2021 Oct; 19(10):1219-1244. PubMed ID: 33719819
    [No Abstract]   [Full Text] [Related]  

  • 34. [From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
    Estella Á; Garnacho-Montero J
    Med Intensiva (Engl Ed); 2020 Nov; 44(8):509-512. PubMed ID: 32423569
    [No Abstract]   [Full Text] [Related]  

  • 35. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
    Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
    Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A
    Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
    Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
    CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.
    Kim MS; An MH; Kim WJ; Hwang TH
    PLoS Med; 2020 Dec; 17(12):e1003501. PubMed ID: 33378357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment options for COVID-19: The reality and challenges.
    Jean SS; Lee PI; Hsueh PR
    J Microbiol Immunol Infect; 2020 Jun; 53(3):436-443. PubMed ID: 32307245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.